9TMQ
Crystal structure of M. tuberculosis PknA in complex with Lestaurtinib
Summary for 9TMQ
| Entry DOI | 10.2210/pdb9tmq/pdb |
| Descriptor | Serine/threonine-protein kinase PknA, Lestaurtinib (3 entities in total) |
| Functional Keywords | protein kinase a, pkna, mtb, inhibitor complex, transferase |
| Biological source | Mycobacterium tuberculosis |
| Total number of polymer chains | 1 |
| Total formula weight | 30975.56 |
| Authors | |
| Primary citation | Pollaniemi, A.,Miao, Y.,Laitila, L.,Piippo, H.,Hammaren, M.,Parikka, M.,Haikarainen, T. Structural insights into multitargeting Mycobacterium tuberculosis Pkn kinases. Microbiol Spectr, :e0004926-e0004926, 2026 Cited by PubMed Abstract: Tuberculosis remains one of the leading major global health challenges, driven by the emergence of multidrug-resistant and extensively drug-resistant bacterial strains. Resistant strains complicate treatment, which often requires prolonged use of toxic second- and third-line drugs. Protein phosphorylation plays critical roles in , with serine/threonine kinases PknA, PknB, and PknG being essential for survival, virulence, and persistence. In this study, we screened an in-house kinase inhibitor library to identify compounds targeting these kinases. Four structurally diverse hits from the screening inhibiting all three kinases were selected for further analysis. Hits were evaluated for their ability to inhibit growth and characterized structurally using X-ray crystallography, molecular docking, and isothermal titration calorimetry. Our findings provide a structural framework for the development of multitargeting kinase inhibitors, offering a potential strategy to combat drug-resistant .IMPORTANCEDrug-resistant tuberculosis is a growing global health threat that is increasingly difficult to treat with existing antibiotics, necessitating the discovery of new therapeutic strategies. This study focuses on protein kinases, key regulatory enzymes that help survive, cause disease, and persist in the host. By identifying small molecules that can simultaneously block multiple essential kinases, this work introduces a promising multitarget approach to combat tuberculosis. Using structural and biophysical methods, we reveal how these compounds interact with their targets, providing a clear blueprint for improving their effectiveness. These insights advance the rational design of next-generation antitubercular drugs and open new avenues for tackling multidrug- and extensively drug-resistant tuberculosis. PubMed: 42446239DOI: 10.1128/spectrum.00049-26 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.13 Å) |
Structure validation
Download full validation report






